Phase 4 Peripheral Neuropathy Trial, Recruiting NCT05721027 Sponsor: Montefiore Medical Center Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Phase 4 Peripheral Neuropathy Trial, Recruiting

NCT05721027
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You visited the emergency department mainly because of sudden lower back pain that shoots down into your buttock or leg (or you have that shooting/tingling sensation even without much back pain).
  • You are being sent home from the emergency department (not admitted to hospital).
  • You are between 18 and 70 years old.
  • Your pain started less than 2 weeks ago.
  • Before this current episode, you had back pain on fewer than half the days over the last 3 months (meaning your back pain is not an ongoing, frequent problem).
  • Your pain was not caused by a significant injury or direct trauma to your back in the past month.
  • Your pain is significantly affecting your ability to do everyday activities, as measured by a standard questionnaire score above 5 out of 24 (confirm with trial site).

Who may not be able to join:

  • You are not able to be contacted or attend follow-up appointments after the initial visit.
  • You are pregnant.
  • You take painkiller medication every day or nearly every day (suggesting a chronic pain condition).
  • You are allergic to or cannot tolerate the medications being studied in this trial.
  • You take steroid medication on a regular, long-term basis.
  • You have a stomach ulcer, frequent indigestion, or have had a gastrointestinal (stomach or bowel) bleed in the past.
  • You have significant heart failure (confirm with trial site).
  • You have reduced kidney function (confirm with trial site).
  • You currently take blood-thinning medication.
  • You have liver cirrhosis or liver inflammation with significantly raised liver levels on blood tests (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Eddie Irizarry, MD, Montefiore Medical Center

Phone: 718-920-6626

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Montefiore Medical Center
Registry
ClinicalTrials.gov
Start date
5 July 2023
Est. completion
1 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Roland Morris Disability Questionnaire (RMDQ) score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov